Valeo Pharma Inc. (VPHIF)
| Market Cap | 4.63M |
| Revenue (ttm) | 38.64M |
| Net Income (ttm) | -23.25M |
| Shares Out | 98.68M |
| EPS (ttm) | -0.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 830 |
| Average Volume | 6,836 |
| Open | 0.0469 |
| Previous Close | 0.0940 |
| Day's Range | 0.0469 - 0.0469 |
| 52-Week Range | 0.0343 - 0.2540 |
| Beta | 1.05 |
| RSI | 42.68 |
| Earnings Date | Jan 29, 2025 |
About Valeo Pharma
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson’s disease; M-Eslon, extended-release morphine sulphate used for ... [Read more]
Full Company ProfileFinancial Performance
In 2023, Valeo Pharma's revenue was 53.91 million, an increase of 94.31% compared to the previous year's 27.75 million. Losses were -27.81 million, 8.01% more than in 2022.
Financial numbers in CAD Financial StatementsNews
VALEO PHARMA ENTERS INTO CANADIAN COMMERCIAL SERVICES AGREEMENT WITH VERU FOR SABIZABULIN IN HOSPITALIZED ADULT PATIENTS WITH COVID-19 AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
In a Phase 3 cinical study interim analysis, sabizabulin showed a 55.2% reduction in deaths compared to placebo in hospitalized adult patients with moderate-severe COVID-19 who are at high risk for AR...
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN ONTARIO, MANITOBA AND NEW BRUNSWICK
Atectura and Enerzair also now reimbursed by the Non-Insured Health Benefits ("NIHB") program of Indigenous Services Canada and Veteran Affairs Canada ("VAC") Public reimbursement now includes Ontario...
VALEO PHARMA'S HESPERCO™ NOW AVAILABLE AT LOBLAWS, HESPERIDIN COVID-19 CLINICAL TRIAL RESULTS SUBMITTED FOR PUBLICATION
Hesperco now available in approximately 300 stores under the Loblaws banners Clinical study yields encouraging results that hesperidin may help reduce COVID-19 associated symptoms MONTREAL, Jan. 5, 20...
Valeo Pharma Announces Upsize of Previously Announced Bought Deal Private Placement of Convertible Debentures to $15 Million With Concurrent $10 Million Private Placement From Investissement Quebec
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS
Valeo Pharma Announces $10 Million Bought Deal Private Placement of Convertible Debentures With Concurrent $10 Million Private Placement From Investissement Quebec
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS
Valeo Pharma Obtains Public Reimbursement For Enerzair® Breezhaler® and Atectura® Breezhaler® In Alberta
First provincial public listing secured for both asthma medications Additional provincial public reimbursement coverage expected to follow soon 85% private payer health plan coverage across Canada MON...
/C O R R E C T I O N from Source -- Valeo Pharma inc./
In the news release, Valeo Pharma Obtains Listings for Redesca in 700 Hospitals and Healthcare Facilities Across Canada, issued 13-Oct-2021 by Valeo Pharma inc. over CNW, we are advised by the company...
Valeo Pharma Obtains Listings for Redesca in 700 Hospitals and Healthcare Facilities Across Canada
2 Group Purchasing Organizations (GPO) listing agreements cover, Redesca™ and Redesca HP™, as well as 3 other Valeo hospital products The 2 multi-year product listings commenced on October 1, 2021 The...
Valeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Enerzair® Breezhaler® and Atectura® Breezhaler®
Agreement to provide framework to participating jurisdictions in support of provincial public listings and reimbursements of both drugs Private payer health plan coverage exceeds 85% across Canada Sci...
Valeo Pharma Announces Additional Provincial Reimbursement Coverage for Redesca™ and Redesca HP™
Redesca™ and Redesca HP™ now covered for public reimbursement in 7 provinces and territories across Canada Private payer health plan coverage in Canada now at 70% MONTREAL, July 13, 2021 /PRNewswire...
Valeo Pharma to Report Second Quarter 2021 Results and Hold Investors Conference Call / Webcast
MONTREAL, June 23, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FSE:VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its finan...
Valeo Pharma Announces Commercial Launch of Enerzair® Breezhaler® and Atectura® Breezhaler®
Product shipments have commenced across Canada National respiratory sales force recruitment well advanced, field deployment on-going Private and public reimbursement coverage progressing Nelly Komari,...
Valeo Pharma Announces $10.0 Million Bought-Deal Public Offering of Units
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Valeo Pharma Provides Update on Private Payer Reimbursement for Enerzair® Breezhaler® and Atectura® Breezhaler®
Private payer health plan coverage in Canada for Enerzair Breezhaler and Atectura Breezhaler has reached 80% Reimbursement proceedings with publicly funded health plans ready to commence MONTREAL, Jun...
Valeo Pharma Projecting Record Revenues for Second Quarter 2021
Record revenues and margins expected for Q2-21 Redesca® launch beginning to impact financial performance Respiratory sales force infrastructure well advanced in support of coming Enerzair® Breezhaler®...
Valeo Pharma's Redesca® and Redesca HP® to Be Covered Under the Ontario Public Drug Benefit Program
Ontario represents 37% of the Canadian low molecular weight heparin market Additional provincial coverage expected to follow MONTREAL, April 28, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB...
Valeo Pharma Upsizes And Closes $6.6 Million Non-Brokered Private Placement
Valeo insiders participation of $2.6 million MONTRÉAL, April 27, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical compan...
Valeo Pharma Announces Commercial Launch of Redesca™ and Redesca HP™
Shipments have commenced across Canada National sales coverage in full deployment through a dedicated key account managers team Private and public reimbursement activities on target. MONTREAL, April 1...
Valeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Redesca® and Redesca HP®
MONTREAL, April 6, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, today announced that it has compl...
Valeo Pharma Inc. Enters into an Agreement for Enerzair® Breezhaler® and Atectura® Breezhaler® in Canada
Valeo to commercialize Enerzair® Breezhaler® and Atectura® Breezhaler®, 2 innovative asthma therapies approved by Health Canada Positions Valeo as one of the leading Canadian Respiratory companies Alm...
Valeo Pharma Announces Major Addition to its Senior Management Team
Frederic Fasano named President and COO Steve Saviuk continues as CEO and becomes Vice-Chairman of the Board of Directors MONTREAL, Jan. 18, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VP...
Valeo Pharma Announces DTC Eligibility for the Trading of Its Shares on the US OTCQB Market
MONTREAL, Dec. 29, 2020 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo"), a Canadian pharmaceutical company, announced today that its common shares are now eligible for ...